India, March 18 -- Scienture Holdings, Inc. (SCNX), a holding company for existing and planned pharmaceutical operating companies, announced Tuesday that the U.S. Food and Drug Administration has approved SCN-102 with the brand name Arbli (losartan potassium) Oral Suspension, 10 mg/mL. Arbli is the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market.
Following a 66.4 percent surge on Monday on the Nasdaq, Scienture shares are currently gaining around 23.8 percent further in the pre-market activity to trade at $3.0700.
SCN-102 is being developed by Scienture Holdings' unit Scienture, LLC. The company expects to commercially launch and make Arbli available to patients in the U.S. in the third quarter.
Arbli is ...